However, blockade of the PD-1/PD-L2 interaction by antibodies stimulates tumor-promoting Th2 inflammation, implying that the unwanted PD-L2 blockade would be a side effect of anti-PD-1 antibodies but not the anti-PD-L1 antibodies (40, 41). Here, PDCD1LG2 is linked to neoplasm.